409 related articles for article (PubMed ID: 28515094)
21. Sclerostin monoclonal antibodies on bone metabolism and fracture healing.
Gamie Z; Korres N; Leonidou A; Gray AC; Tsiridis E
Expert Opin Investig Drugs; 2012 Oct; 21(10):1523-34. PubMed ID: 22849579
[TBL] [Abstract][Full Text] [Related]
22. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
23. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size.
Kogawa M; Khalid KA; Wijenayaka AR; Ormsby RT; Evdokiou A; Anderson PH; Findlay DM; Atkins GJ
Am J Physiol Cell Physiol; 2018 Jan; 314(1):C53-C61. PubMed ID: 28978523
[TBL] [Abstract][Full Text] [Related]
24. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
25. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.
Tsourdi E; Lademann F; Ominsky MS; Rijntjes E; Köhrle J; Misof BM; Roschger P; Klaushofer K; Hofbauer LC; Rauner M
Endocrinology; 2017 Nov; 158(11):3765-3777. PubMed ID: 28973221
[TBL] [Abstract][Full Text] [Related]
28. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
29. [Anti-sclerostin antibodies].
Okazaki R
Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
[TBL] [Abstract][Full Text] [Related]
30. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
[TBL] [Abstract][Full Text] [Related]
31. The future of osteoporosis treatment - a research update.
Lippuner K
Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
[TBL] [Abstract][Full Text] [Related]
32. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
33. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
34. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
35. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.
Faraahi Z; Baud'huin M; Croucher PI; Eaton C; Lawson MA
Bone; 2019 May; 122():82-92. PubMed ID: 30776499
[TBL] [Abstract][Full Text] [Related]
36. Retention of osteocytic micromorphology by sclerostin antibody in a concurrent ovariectomy and functional disuse model.
Zhang D; Miranda M; Li X; Han J; Sun Y; Rojas N; He S; Hu M; Lin L; Li X; Ke HZ; Qin YX
Ann N Y Acad Sci; 2019 Apr; 1442(1):91-103. PubMed ID: 30644553
[TBL] [Abstract][Full Text] [Related]
37. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
[TBL] [Abstract][Full Text] [Related]
38. [Newly developed drugs to improve bone strength].
Hagino H
Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
[TBL] [Abstract][Full Text] [Related]
39. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.
Liu W; Wang Z; Yang J; Wang Y; Li K; Huang B; Yan B; Wang T; Li M; Zou Z; Yang J; Xiao G; Cui ZK; Liu A; Bai X
Open Biol; 2019 May; 9(5):180262. PubMed ID: 31088250
[TBL] [Abstract][Full Text] [Related]
40. Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse.
Macias BR; Swift JM; Nilsson MI; Hogan HA; Bouse SD; Bloomfield SA
J Appl Physiol (1985); 2012 Mar; 112(5):918-25. PubMed ID: 22174402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
